Statistics for Relmada Therapeutics (id:8379 RLMD)
Valuation metrics
Market cap
95.35M
Enterprise value
27.93M
Trailing P/E (ttm)
-0.85
Forward P/E
-1.57
PEG ratio
-1.57
Price/Sales (ttm)
Price/Book (mrq)
1.11
Enterprise Value/Revenue
Enterprise Value/EBITDA
-0.27
Overview
Shares outstanding
30.17M
Float
27.54M
Shares short
1.26M
% Held by insiders
0.08%
% Held by institutions
0.46%
Average volume (10 days)
106.38K
Average volume (90 days)
Price summary
52-Week low
1.88
52-Week high
7.22
52-Week change
-1.79%
Beta
0.42
50-Day moving average
3.34
200-Day moving average
3.84
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
September 30th, 2019
Ex-dividend date
Last split factor
2:1
Last split date
September 30th, 2019
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
0.00%
Operational effectiveness
Return on assets
-59.13%
Return on equity
-100.40%
Income statement
Revenue (ttm)
0.00
Revenue per share (ttm)
0.00
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
0.00
Net income to common (ttm)
-86,763,464.00
Diluted EPS (ttm)
-2.86
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
70.44M
Total cash per share (mrq)
2.33
Total debt (mrq)
0.00
Total Debt/Equity (mrq)
0.00
Current ratio (mrq)
744.20%
Book value per share (mrq)
2.84
Cash flow
Cash flow statement
-48,180,616.00
Levered free cash flow (LFCF)
-18,512,976.00